CBL0137

DRUG3 trials

Sponsors

Incuron, Fox Chase Cancer Center

Conditions

GlioblastomaHematological MalignanciesLocally Advanced or Metastatic MelanomaSolid Tumors

Early Phase 1

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

RecruitingNCT05498792

Fox Chase Cancer CenterLocally Advanced or Metastatic Melanoma

Start: 2022-11-30End: 2027-09-02Target: 12Updated: 2026-05-22

Phase 1

A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm

CompletedNCT01905228

IncuronGlioblastoma, Solid Tumors

Start: 2013-07-31End: 2019-06-30Updated: 2020-12-10

Study of IV CBL0137 in Previously Treated Hematological Subjects

TerminatedNCT02931110

IncuronHematological Malignancies

Start: 2017-01-31End: 2020-10-31Updated: 2020-12-10

Related Papers

Results of a completed phase I trial of CBL0137 administered intravenously (IV) to patients (Pts) with advanced solid tumors.

Journal of Clinical Oncology2020-05-2020 citations